Klaeger et al. showed that the FDA-approved MET/VEGFR inhibitor, cabozantinib, effectively inhibited the tyrosine kinase fusion product FLT3-ITD to potentially cure acute myeloid leukemia [78, 79]. Here, MET is linked to acute myeloid leukemia.